Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter L Greenberg

Showing results (11-20 of 93) with videos related to

Pageof 10
Sort By:
Blood Advances|October 25, 2018
Molecular pathophysiology of the myelodysplastic syndromes: insights for targeted therapyAlex Aleshin, Peter L Greenberg
Journal of the National Comprehensive Cancer Network : JNCCN|September 25, 2009
Novel biospecific agents for the treatment of myelodysplastic syndromesJason Gotlib, Peter L Greenberg
Journal of the National Comprehensive Cancer Network : JNCCN|December 12, 2022
Recent Clinical and Molecular Advances for the Classification of Myelodysplastic NeoplasmsAmy E DeZern, Peter L Greenberg
Best Practice & Research. Clinical Haematology|February 10, 2015
MDS prognostic scoring systems – past, present, and futureBrian A Jonas, Peter L Greenberg
Blood|August 10, 2023
The trajectory of prognostication and risk stratification for patients with myelodysplastic syndromesAmy E DeZern, Peter L Greenberg
Critical Reviews in Oncology/Hematology|June 28, 2005
Management of patients with higher risk myelodysplastic syndromesJon S Fukumoto, Peter L Greenberg
Hematology. American Society of Hematology. Education Program|November 26, 2002
Myelodysplastic syndromesPeter L Greenberg, Neal S Young, Norbert Gattermann
Blood|February 2, 2024
How I reduce and treat posttransplant relapse of MDSAlain Mina, Peter L Greenberg, H Joachim Deeg
American Journal of Hematology|July 23, 2008
International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: impact of cytopenias on clinical outcomes in myelodysplastic syndromesJelena M Kao, Alex McMillan, Peter L Greenberg
Leukemia & Lymphoma|February 27, 2016
Immune checkpoint pathways: perspectives on myeloid malignanciesGabriel A Rivera, Iman Saramipoor Behbahan, Peter L Greenberg
Pageof 10

Showing results (11-20 of 93) with videos related to

Sort By:
Pageof 10
Blood Advances|October 25, 2018
Molecular pathophysiology of the myelodysplastic syndromes: insights for targeted therapyAlex Aleshin, Peter L Greenberg
Journal of the National Comprehensive Cancer Network : JNCCN|September 25, 2009
Novel biospecific agents for the treatment of myelodysplastic syndromesJason Gotlib, Peter L Greenberg
Journal of the National Comprehensive Cancer Network : JNCCN|December 12, 2022
Recent Clinical and Molecular Advances for the Classification of Myelodysplastic NeoplasmsAmy E DeZern, Peter L Greenberg
Best Practice & Research. Clinical Haematology|February 10, 2015
MDS prognostic scoring systems – past, present, and futureBrian A Jonas, Peter L Greenberg
Blood|August 10, 2023
The trajectory of prognostication and risk stratification for patients with myelodysplastic syndromesAmy E DeZern, Peter L Greenberg
Critical Reviews in Oncology/Hematology|June 28, 2005
Management of patients with higher risk myelodysplastic syndromesJon S Fukumoto, Peter L Greenberg
Hematology. American Society of Hematology. Education Program|November 26, 2002
Myelodysplastic syndromesPeter L Greenberg, Neal S Young, Norbert Gattermann
Blood|February 2, 2024
How I reduce and treat posttransplant relapse of MDSAlain Mina, Peter L Greenberg, H Joachim Deeg
American Journal of Hematology|July 23, 2008
International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: impact of cytopenias on clinical outcomes in myelodysplastic syndromesJelena M Kao, Alex McMillan, Peter L Greenberg
Leukemia & Lymphoma|February 27, 2016
Immune checkpoint pathways: perspectives on myeloid malignanciesGabriel A Rivera, Iman Saramipoor Behbahan, Peter L Greenberg
Pageof 10